Get the Stockscreener App
36.56
3.78%
1.33
Maplight Therapeutics Inc stock is traded at $36.56, with a volume of 547.38K.
It is up +3.78% in the last 24 hours and up +19.28% over the past month.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
See More
Previous Close:
$35.23
Open:
$35.46
24h Volume:
547.38K
Relative Volume:
1.32
Market Cap:
$1.66B
Revenue:
-
Net Income/Loss:
$-161.15M
P/E Ratio:
-9.8414
EPS:
-3.7149
Net Cash Flow:
$-138.61M
1W Performance:
-3.46%
1M Performance:
+19.28%
6M Performance:
+103.34%
1Y Performance:
+0.00%
1-Day Range:
$34.38
$36.97
1-Week Range:
$34.38
$38.92
52-Week Range:
$12.24
$40.43
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
650-839-4360
Address
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
36.56 | 1.66B | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Needham | Buy |
| Apr-07-26 | Initiated | TD Cowen | Buy |
| Mar-19-26 | Initiated | Canaccord Genuity | Buy |
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
View All
Maplight Therapeutics Inc Stock (MPLT) Latest News
Canaccord raises MapLight Therapeutics price target on trial data By Investing.com - Investing.com Canada
MAPLIGHT THERAPEUTICS INC : CANACCORD GENUITY RAISES TARGET PRICE TO $43 FROM $35 - Bitget
Possible Bearish Signals With MapLight Therapeutics Insiders Disposing Stock - simplywall.st
Wall Street Analysts Are Bullish on Top NA Picks - The Globe and Mail
Maplight Therapeutics (NASDAQ:MPLT) Upgraded by BMO Capital Markets to Strong-Buy Rating - MarketBeat
Form 4 MapLight Therapeutics Inc For: 21 July By Investing.com - Investing.com South Africa
MapLight Therapeutics CSO James Woodruff sells $673k in shares for tax - Investing.com UK
MapLight Therapeutics Seen Having Upside in Schizophrenia Trial Readout, UBS Says - marketscreener.com
BMO Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $46 - Moomoo
UBS Adjusts MapLight Therapeutics Price Target to $52 From $48, Maintains Buy Rating - Moomoo
MPLT Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
UBS raises MapLight Therapeutics stock price target on trial data By Investing.com - Investing.com Canada
MapLight Therapeutics general counsel sells $607,870 in shares By Investing.com - Investing.com South Africa
MapLight Therapeutics CEO Kroeger sells $5.4m in company stock - Investing.com
MapLight Therapeutics CEO Kroeger sells $5.4m in company stock By Investing.com - Investing.com UK
MapLight Therapeutics general counsel sells $607,870 in shares - Investing.com
BMO Capital Initiates MapLight Therapeutics at Outperform With $46 Price Target - marketscreener.com
BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $46 - Moomoo
MapLight Therapeutics (MPLT) Coverage Initiated with Outperform Rating and Price Target - GuruFocus
Form 4 MapLight Therapeutics Inc For: 20 July By Investing.com - Investing.com Nigeria
MapLight Therapeutics (MPLT) CDO sells 36K shares via tax and plan trades - Stock Titan
MapLight Therapeutics (MPLT) CAO and interim CFO reports 36,979-share stock sale - Stock Titan
MapLight Therapeutics Insider Sold Shares Worth $5,443,722, According to a Recent SEC Filing - marketscreener.com
Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer disposes of USD 1.34 million in common shares - Bitget
Maplight Therapeutics CMO Erin Pennock Foff sells USD 1.99 million in common shares - Bitget
Form 144 MapLight Therapeutics For: 17 July By Investing.com - Investing.com Nigeria
MapLight Therapeutics CSO Lillie James Woodruff sells $673K in shares - Investing.com India
Form 4 MapLight Therapeutics Inc For: 17 July By Investing.com - Investing.com South Africa
MapLight Therapeutics CMO sells $1.73m in stock By Investing.com - Investing.com South Africa
MapLight Therapeutics CSO Lillie James Woodruff sells $673K in shares By Investing.com - Investing.com South Africa
MapLight Therapeutics (MPLT) CMO reports 47,158-share stock sale - Stock Titan
MapLight Therapeutics CEO Christopher Kroeger sells $5.44m in stock By Investing.com - Investing.com India
MapLight Therapeutics CEO Christopher Kroeger sells $5.44m in stock - Investing.com India
Form 144 MapLight Therapeutics For: 17 July - Investing.com India
Form 144 MapLight Therapeutics For: 15 July By Investing.com - Investing.com Nigeria
Maplight Therapeutics (NASDAQ:MPLT) Trading Down 5.4%Here's What Happened - MarketBeat
MapLight Therapeutics (NASDAQ: MPLT) files notice for 36,284-share sale - Stock Titan
Analyst Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target Amid Optimism for ML-007C-MA - TipRanks
MapLight Therapeutics (MPLT) Slips 7% as Stock Tests Key Support LevelsHigh Dividend Factor - dars.gov.et
Maplight Therapeutics (NASDAQ:MPLT) Sees Large Volume Increase on Analyst Upgrade - MarketBeat
Can ZEPHYR Schizophrenia Trial Data Light Up MapLight? - RTTNews
Needham raises MapLight Therapeutics stock price target on trial data - Investing.com
Needham & Company LLC Raises Maplight Therapeutics (NASDAQ:MPLT) Price Target to $45.00 - MarketBeat
Needham raises MapLight Therapeutics stock price target on trial data By Investing.com - Investing.com Canada
MPLTMapLight Therapeutics Inc Options - Finviz
MapLight Therapeutics autism drug shows mixed potential in adolescents - MSN
Analyst Maintains Buy on MapLight Therapeutics, Reaffirms $45 Price Target Ahead of Key Phase 2 ZEPHYR Readout - TipRanks
MapLight Therapeutics Faces Key Catalyst as ZEPHYR Trial Readout ApproachesEstimate Revision Count - DonanımHaber
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout? - Yahoo Finance
Number of shareholders of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Maplight Therapeutics Inc Stock (MPLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maplight Therapeutics Inc Stock (MPLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GILLIS JONATHAN | CAO and Interim CFO |
Jul 15 '26 |
Sale |
36.51 |
10,055 |
367,093 |
171,164 |
| GILLIS JONATHAN | CAO and Interim CFO |
Jul 16 '26 |
Sale |
36.80 |
8,455 |
311,112 |
162,709 |
| Kreitzer Anatol | Chief Discovery Officer |
Jul 17 '26 |
Sale |
37.60 |
17,173 |
645,719 |
174,906 |
| Kreitzer Anatol | Chief Discovery Officer |
Jul 15 '26 |
Sale |
36.49 |
10,055 |
366,940 |
201,135 |
| Kreitzer Anatol | Chief Discovery Officer |
Jul 16 '26 |
Sale |
36.80 |
9,056 |
333,235 |
192,079 |
| Kroeger Christopher A. | Chief Executive Officer |
Jul 16 '26 |
Sale |
36.79 |
69,082 |
2,541,341 |
1,263,234 |
| Kroeger Christopher A. | Chief Executive Officer |
Jul 15 '26 |
Sale |
36.69 |
61,778 |
2,266,457 |
1,332,316 |
| Kroeger Christopher A. | Chief Executive Officer |
Jul 17 '26 |
Sale |
37.90 |
16,779 |
635,924 |
1,246,455 |
| Lillie James Woodruff | Chief Scientific Officer |
Jul 16 '26 |
Sale |
36.79 |
8,547 |
314,412 |
226,539 |
| Lillie James Woodruff | Chief Scientific Officer |
Jul 15 '26 |
Sale |
36.70 |
7,643 |
280,506 |
235,086 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):